US Edition
AstraZeneca Forms an AI Deal in China; Third Harmonic Advances Liquidation Plans
6 Articles
6 Articles
The laboratory has entered into a partnership with the CSPC laboratory, which could have a value of up to $5 billion.
The multinational pharmaceutical and biotechnology company AstraZeneca presented on Friday a collaboration of research assisted by artificial intelligence with its Chinese counterpart CSPC Pharmaceuticals, in an agreement valued at 5 billion dollars, says the AFP note. "This strategic research collaboration underlines our commitment to innovation to address chronic diseases that affect [...] The entry AstraZeneca establishes an alliance of resea…
humenglish.com
Macau BusinessAstraZeneca inks China AI research deal for chronic diseases
LONDON: AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fine…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
To view factuality data please Upgrade to Premium
